Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients

NACompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

October 31, 2010

Study Completion Date

October 31, 2010

Conditions
ConstipationPalliative Care
Interventions
DRUG

Docusate Sodium, Sennoside

"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.~Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."

DRUG

Sennoside + Placebo

"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.~Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"

Trial Locations (3)

T5G 3A2

CapitalCare Norwood, Edmonton

T5K 0A1

Mel Miller Hospice at Edmonton General Continuing Care Hospital, Edmonton

T6J 6W1

St. Joseph's Auxiliary Care Hospital, Edmonton

All Listed Sponsors
collaborator

College of Family Physicians of Canada

OTHER

collaborator

Covenant Health, Canada

OTHER

collaborator

Capital Care

UNKNOWN

lead

University of Alberta

OTHER

NCT00902031 - Effectiveness of Docusate in Preventing/Treating Constipation in Palliative Care Patients | Biotech Hunter | Biotech Hunter